We also accounted for the increased frequency of gastrointestinal side effects and pancreatitis (in the GLP-1 receptor agonist cases) and the increased frequency of urogenital infections and ketoacidosis (in the SGLT-2 inhibitor cases). The gene discussed is GLP1R; the disease is pancreatitis.